行情

EYEG

EYEG

Eyegate制药
NASDAQ

实时行情|Nasdaq Last Sale

2.000
+0.100
+5.26%
盘后: 1.950 -0.05 -2.50% 19:59 09/17 EDT
开盘
1.900
昨收
1.900
最高
2.020
最低
1.730
成交量
376.25万
成交额
--
52周最高
8.18
52周最低
1.440
市值
2,523.85万
市盈率(TTM)
-1.1930
分时
5日
1月
3月
1年
5年
36 只股票在周二的中盘交易
Gainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results. BELLUS Health Inc. (NASDAQ: BLU) shares climbed 25.5% to $6.00. The company on Monday announced interim analysis from the Ph...
Benzinga · 4天前
NNVC、LIFE 和 DATS 上市前的赢家
Communications Systems JCS +27% declares $3.50 special dividend NanoViricides (NYSE:NNVC) +21% completes licensing for Coronavirus field which includes current COVID-19 drug development aTyr Pharma (NASDAQ:LIFE) +13%. DatChat (NASDAQ:DATS) +10%. SeaChange ...
Seekingalpha · 4天前
周二盘前交易时段 20 只股票
Gainers Communications Systems, Inc. (NASDAQ: JCS) rose 34.8% to $9.15 in pre-market trading as the company declared a special dividend of $3.50 per share.
Benzinga · 4天前
EyeGate 将出席 HC Wainwright 第 23 届年度全球投资会议
EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), ("EyeGate" or the "Company"), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that EyeGate's President and Chief Execu...
GlobeNewswire · 09/09 20:15
EyeGate Pharma 完成了第 2 阶段概念验证研究的目标注册,以评估 PP-001治疗眼表炎症的效果
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases,
Benzinga · 09/08 10:55
EyeGate Pharma 在第 2 阶段的概念验证研究中完成目标注册,以评估 PP-001治疗眼表炎症的效果
-Proof-of-concept study conducted in Austria; Study designed to build upon positive Phase 1 safety data in healthy volunteers-
GlobeNewswire · 09/08 10:55
The Daily Biotech Pulse:礼来重组神经科学业务部门,Helius Medical 获得突破性指定,Ra Medical 出售皮肤科业务
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
HC Wainwright & Co. 维持对 Eyegate Pharmaceuticals 的买入,将目标价下调至 11 美元
HC Wainwright & Co. analyst Yi Chen maintains Eyegate Pharmaceuticals (NASDAQ:EYEG) with a Buy and lowers the price target from $14 to $11.
Benzinga · 08/16 14:20
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解EYEG最新的财务预测,通过EYEG每股收益,每股净资产,每股现金流等数据分析Eyegate制药近期的经营情况,然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测EYEG价格均价为11.83,最高价位15.00,最低价为9.50。
EPS
机构持股
总机构数: 30
机构持股: 379.99万
持股比例: 30.11%
总股本: 1,261.93万
类型机构数股数
增持
4
8.56万
建仓
1
1,000
减持
5
11.78万
平仓
2
1.26万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-0.39%
制药与医学研究
-0.10%
高管信息
Chairman/Executive Director
Stephen From
President/Chief Executive Officer/Director
Brian Strem
Chief Financial Officer
Sarah Romano
Executive Vice President
Franz Obermayr
Lead Director/Independent Director
Paul Chaney
Independent Director
Kenneth Gayron
Independent Director
Aron Shapiro
Independent Director
Praveen Tyle
暂无数据
EYEG 简况
Eyegate Pharmaceuticals, Inc是一家临床阶段的制药公司。该公司致力于开发和商业化治疗炎症和免疫疾病的产品,重点是眼部和神经系统。该公司的技术平台PP-001是一种非甾体、免疫调节和小分子二氢乳清酸脱氢酶(DHODH)抑制剂。PP-001已开发成两种临床阶段的眼科制剂:PaniJect,是一种玻璃体内注射剂,用于治疗包括后葡萄膜炎在内的眼部炎症性疾病;PaniDrop,是一种纳米载体技术滴眼液,用于治疗结膜炎、干眼症等眼表疾病 疾病等。该公司还在开发Ocular Bandage Gel(OBG),它是一种天然聚合物透明质酸,旨在保护眼表,使角膜上皮再生并改善眼表完整性。

微牛提供Eyegate Pharmaceuticals Inc(NASDAQ-EYEG)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的EYEG股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易EYEG股票基本功能。